Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Bayer Builds China Diabetes Portfolio with SciLin Launch

publication date: Sep 7, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Bayer Schering Pharma has launched SciLin, its recombinant insulin product, in China. In June 2009, the company paid $43.5 million to Polish biotech Bioton for China rights to the drug over the next 15 years. At the time of the agreement, Bayer forecast that SciLin would generate between $1.5 billion and $2 billion of revenue in China during the life of the agreement. More details....

Stock Symbol: (XETRA: BAY)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...